SOBI wins FDA nod for Kineret in NOMID
This article was originally published in Scrip
Executive Summary
The US FDA approved Swedish Orphan Biovitrum's Kineret (anakinra) as the first and only treatment in the US for children and adults with neonatal-onset multisystem inflammatory disease (NOMID), the most severe form of cryopyrin associated periodic syndromes (CAPS), a group of rare inherited autoinflammatory diseases.